An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
Part of paid clinical trials in New Orleans, Louisiana.
- Sponsor
- AstraZeneca
- Study ID
- NCT03259633
- Status
- Approved For Marketing
Conditions
- NF type1 With Inoperable Plexiform Neurofibromas
Eligibility Criteria
- Sex
- ALL
- Age
- 2 Years - 130 Years
- Healthy Volunteers
- Not accepted
Interventions
- Selumetinib — DRUGopen-label, single-arm, multicenter intermediate access protocol
Study Details
This will be an open-label, single-arm, multicenter intermediate access protocol which provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1 (NF1) who have inoperable, progressive/symptomatic plexiform neurofibromas (PN) without any alternative therapeutic options. All patients will continue to receive drug while they are deriving clinical benefit. Approximately 100 patients in the US will be treated as part of this protocol
Key Dates
- Status verified
- Apr 2020
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | New Orleans | Louisiana | 12345 | - |
Find similar trials in New Orleans, LA
By research site